Literature DB >> 16341038

Mutational screen reveals a novel JAK2 mutation, L611S, in a child with acute lymphoblastic leukemia.

C P Kratz, S Böll, U Kontny, M Schrappe, C M Niemeyer, M Stanulla.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16341038     DOI： 10.1038/sj.leu.2404060

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  22 in total

Review 1.  Jak2 inhibitors: rationale and role as therapeutic agents in hematologic malignancies.

Authors:  Jacqueline Sayyah; Peter P Sayeski
Journal:  Curr Oncol Rep       Date:  2009-03       Impact factor: 5.075

Review 2.  JAK2 V617F in myeloid disorders: molecular diagnostic techniques and their clinical utility: a paper from the 2005 William Beaumont Hospital Symposium on Molecular Pathology.

Authors:  David P Steensma
Journal:  J Mol Diagn       Date:  2006-09       Impact factor: 5.568

3.  Mechanistic insights into activation and SOCS3-mediated inhibition of myeloproliferative neoplasm-associated JAK2 mutants from biochemical and structural analyses.

Authors:  Leila N Varghese; Daniela Ungureanu; Nicholas P D Liau; Samuel N Young; Artem Laktyushin; Henrik Hammaren; Isabelle S Lucet; Nicos A Nicola; Olli Silvennoinen; Jeffrey J Babon; James M Murphy
Journal:  Biochem J       Date:  2014-03-01       Impact factor: 3.857

4.  The landscape of somatic mutations in Down syndrome-related myeloid disorders.

Authors:  Kenichi Yoshida; Tsutomu Toki; Yusuke Okuno; Rika Kanezaki; Yuichi Shiraishi; Aiko Sato-Otsubo; Masashi Sanada; Myoung-ja Park; Kiminori Terui; Hiromichi Suzuki; Ayana Kon; Yasunobu Nagata; Yusuke Sato; RuNan Wang; Norio Shiba; Kenichi Chiba; Hiroko Tanaka; Asahito Hama; Hideki Muramatsu; Daisuke Hasegawa; Kazuhiro Nakamura; Hirokazu Kanegane; Keiko Tsukamoto; Souichi Adachi; Kiyoshi Kawakami; Koji Kato; Ryosei Nishimura; Shai Izraeli; Yasuhide Hayashi; Satoru Miyano; Seiji Kojima; Etsuro Ito; Seishi Ogawa
Journal:  Nat Genet       Date:  2013-09-22       Impact factor: 38.330

Review 5.  JAK kinase targeting in hematologic malignancies: a sinuous pathway from identification of genetic alterations towards clinical indications.

Authors:  Lorraine Springuel; Jean-Christophe Renauld; Laurent Knoops
Journal:  Haematologica       Date:  2015-10       Impact factor: 9.941

6.  Germline JAK2 L611S mutation in a child with thrombocytosis.

Authors:  Bernard Aral; Martine Courtois; Sylviane Ragot; Valentin Bourgeois; Elodie Bottolier-Lemallaz; Claire Briandet; François Girodon
Journal:  Haematologica       Date:  2018-03-22       Impact factor: 9.941

Review 7.  A structure-function perspective of Jak2 mutations and implications for alternate drug design strategies: the road not taken.

Authors:  K Gnanasambandan; P P Sayeski
Journal:  Curr Med Chem       Date:  2011       Impact factor: 4.530

Review 8.  Molecular pathways: molecular basis for sensitivity and resistance to JAK kinase inhibitors.

Authors:  Sara C Meyer; Ross L Levine
Journal:  Clin Cancer Res       Date:  2014-02-28       Impact factor: 12.531

9.  The acute lymphoblastic leukemia-associated JAK2 L611S mutant induces tumorigenesis in nude mice.

Authors:  Megumi Funakoshi-Tago; Kenji Tago; Kazuya Sumi; Miyuki Abe; Eriko Aizu-Yokota; Tomoyuki Oshio; Yoshiko Sonoda; Tadashi Kasahara
Journal:  J Biol Chem       Date:  2009-03-16       Impact factor: 5.157

Review 10.  Down syndrome and malignancies: a unique clinical relationship: a paper from the 2008 william beaumont hospital symposium on molecular pathology.

Authors:  Ana C Xavier; Yubin Ge; Jeffrey W Taub
Journal:  J Mol Diagn       Date:  2009-09       Impact factor: 5.568
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.